Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Capital Expenditures (2023 - 2024)

Lexicon Pharmaceuticals (LXRX) has disclosed Capital Expenditures for 5 consecutive years, with $474000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Capital Expenditures changed N/A to $474000.0 in Q4 2024 year-over-year; TTM through Dec 2025 was $781000.0, a 24.25% decrease, with the full-year FY2024 number at $1.0 million, up 119.36% from a year prior.
  • Capital Expenditures was $474000.0 for Q4 2024 at Lexicon Pharmaceuticals, up from $307000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $474000.0 in Q4 2024 to a low of $83000.0 in Q3 2023.